Clinical Trials Logo

Filter by:
NCT ID: NCT00865020 Completed - Hypertension Clinical Trials

Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal

ASSERTIVE
Start date: March 2009
Phase: Phase 4
Study type: Interventional

This study was specifically designed to provide additional information on the mechanism of action of direct renin inhibition postulating the higher-level RAS cascade inhibition. The purpose of this study was to compare the prolonged efficacy and safety of aliskiren to that of telmisartan in mild to moderate hypertensive patients in the 24 hrs Ambulatory Blood Pressure Monitoring setting after a one week treatment withdrawal.

NCT ID: NCT00865007 Completed - HIV Infections Clinical Trials

Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy

KRETA
Start date: December 2008
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the efficacy for the recovery of peripheral fat of lopinavir/ritonavir in monotherapy versus abacavir/lamivudine and lopinavir/ritonavir in subjects who developed lipoatrophy while receiving zidovudine plus lamivudine plus abacavir.

NCT ID: NCT00864552 Completed - Hemophilia A Clinical Trials

International PMS Study - KOGENATE Bayer

Start date: December 2002
Phase: N/A
Study type: Observational

To evaluate long-term safety (primarily by recording adverse events including inhibitors), efficacy and patient acceptance of KOGENATE Bayer in home treatment either on prophylaxis or on demand. To evaluate both safety and efficacy with respect to lot variability, in particular regarding lot-groups formulated with or without fix between.

NCT ID: NCT00864253 Completed - Malignant Melanoma Clinical Trials

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Start date: April 23, 2009
Phase: Phase 3
Study type: Interventional

The main purpose of this research study is to compare the safety, tolerability, and anti tumor activity of an investigational drug, ABI-007 versus Dacarbazine in patients with metastatic melanoma who have not previously received chemotherapy. ABI-007 is a new preparation of the active drug paclitaxel. It contains the same medication as the prescription chemotherapy drug Abraxane®. Abraxane® is approved by the FDA for the treatment of metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Dacarbazine is approved by the FDA for the treatment of melanoma. In this study, ABI-007 and Dacarbazine will be tested as therapy for people who have not yet had any cancer treatment for the diagnosis of metastatic melanoma.

NCT ID: NCT00863746 Completed - Carcinoma Clinical Trials

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

MISSION
Start date: April 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to see if sorafenib plus best supportive care (i.e. in addition to the non-cancer treatments patients would normally receive) is an effective treatment for lung cancer compared to best supportive care alone. The safety and tolerability of the two treatment groups will also be compared. The goal of the study is to test the ability of sorafenib to improve survival compared to best supportive care alone.

NCT ID: NCT00863655 Completed - Breast Cancer Clinical Trials

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

BOLERO-2
Start date: June 2009
Phase: Phase 3
Study type: Interventional

There are no treatments specifically approved after recurrence or progression on a non steroidal aromatase inhibitors (NSAI). In light of the need for new treatment options for postmenopausal women after failure of prior NSAI therapy, the purpose of this Phase III study is to compare efficacy and safety of a treatment with exemestane + everolimus to exemestane + placebo in postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer refractory to NSAI.

NCT ID: NCT00863577 Completed - Healthy Clinical Trials

Pharmacokinetic Study of Two Oral Bemiparin Formulations

Start date: March 2009
Phase: Phase 1
Study type: Interventional

The primary pharmacokinetic analysis will be the correlation of the AUC amidolytic anti-Xa activity

NCT ID: NCT00863213 Completed - Atrial Fibrillation Clinical Trials

Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation

SARA
Start date: March 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effectivity and safety of atrial fibrillation ablation, in comparison to antiarrhythmic drug therapy in patients with refractory, persistent atrial fibrillation.

NCT ID: NCT00863135 Completed - Clinical trials for Obstructive Sleep Apnea

Effect of CPAP on Blood Pressure in Patients With Sleep Apnea and Refractory Hypertension

Start date: December 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effects of CPAP treatment on blood pressure in patients with sleep apnea syndrome (SAS) and refractory arterial hypertension (RAH). Also, some of the mechanisms mediating SAS and RAH (systemic inflammation, oxidative stress, sympathetic hyperactivity) will be analyzed.

NCT ID: NCT00862784 Completed - Clinical trials for Colorectal Carcinoma

A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer

Start date: April 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test how long participants with colorectal cancer live without progressive disease when being treated with IMC-1121B (ramucirumab) and the modified FOLFOX-6 chemotherapy.